Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial

The Lancet ◽  
2000 ◽  
Vol 355 (9198) ◽  
pp. 93-97 ◽  
Author(s):  
William F Carman ◽  
Alexander G Elder ◽  
Lesley A Wallace ◽  
Karen McAulay ◽  
Andrew Walker ◽  
...  
Keyword(s):  
Health Care ◽  
Randomised Controlled Trial ◽  
Influenza Vaccination ◽  
Health Care Workers ◽  
Long Term Care ◽  
Controlled Trial ◽  
Term Care ◽  
Care Workers ◽  
Randomised Controlled

scholarly journals Influenza Vaccination of Health Care Workers in Long-Term Care Protects Elderly Patients

1998 ◽  
Vol 27 (suppl 2) ◽  
pp. 45-46 ◽  
Author(s):  
D. J. Stott ◽  
G. D. Murray ◽  
A. Elder ◽  
W. B. Carman ◽  
Keyword(s):  
Health Care ◽  
Elderly Patients ◽  
Influenza Vaccination ◽  
Health Care Workers ◽  
Long Term Care ◽  
Term Care ◽  
Care Workers

scholarly journals Influenza Vaccination of Health Care Workers in Long-Term-Care Hospitals Reduces the Mortality of Elderly Patients

1997 ◽  
Vol 175 (1) ◽  
pp. 1-6 ◽  
Author(s):  
J. Potter ◽  
D. J. Stott ◽  
M. A. Roberts ◽  
A. G. Elder ◽  
B. O'Donnell ◽  
...  
Keyword(s):  
Health Care ◽  
Elderly Patients ◽  
Influenza Vaccination ◽  
Health Care Workers ◽  
Long Term Care ◽  
Term Care ◽  
Care Workers

scholarly journals The Impact of Rhode Island's Mandatory Health Care Worker Influenza Vaccination Regulation on Influenza Incidence in Long-Term Care Facility Residents

2018 ◽  
Author(s):  
Wendy Chicoine
Keyword(s):  
Health Care ◽  
Influenza Vaccination ◽  
Rhode Island ◽  
Health Care Workers ◽  
Long Term Care ◽  
Care Facility ◽  
Term Care ◽  
Care Workers ◽  
The Impact

Seasonal influenza is a serious public health problem that contributes to significant morbidity and mortality locally, nationally, and globally. The Centers for Disease Control and Prevention (CDC) estimates that influenza has caused between 9.2 million and 60.8 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010, and approximately 80- 90 percent of influenza related deaths occurred in people 65 years and older. In 2012, prompted by the mounting\ evidence of the risk of nosocomial influenza infection for patients and low influenza vaccination rates of health care workers, the Rhode Island Department of Health (RIDOH) amended its Rules and Regulations for Immunization and Testing for Healthcare Workers. This amendment included mandatory influenza vaccinations for all health care workers, students, volunteers, and trainees who have direct patient contact within a health care facility. The purpose of this study was to evaluate the impact of the regulation of mandating influenza vaccination for health care workers in Rhode Island on influenza incidence, hospitalizations, and deaths of residents of long-term care facilities (LTCF). Surveillance data for influenza incidence, hospitalizations, and deaths among residents of LTCF pre and post the policy implementation are analyzed and results presented. Policy and practice implications for public health nursing are discussed.

scholarly journals The Impact of Rhode Island's Mandatory Health Care Worker Influenza Vaccination Regulation on Influenza Incidence in Long-Term Care Facility Residents

2018 ◽  
Author(s):  
Wendy Chicoine
Keyword(s):  
Health Care ◽  
Influenza Vaccination ◽  
Rhode Island ◽  
Health Care Workers ◽  
Long Term Care ◽  
Care Facility ◽  
Term Care ◽  
Care Workers ◽  
The Impact

Seasonal influenza is a serious public health problem that contributes to significant morbidity and mortality locally, nationally, and globally. The Centers for Disease Control and Prevention (CDC) estimates that influenza has caused between 9.2 million and 60.8 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010, and approximately 80- 90 percent of influenza related deaths occurred in people 65 years and older. In 2012, prompted by the mounting\ evidence of the risk of nosocomial influenza infection for patients and low influenza vaccination rates of health care workers, the Rhode Island Department of Health (RIDOH) amended its Rules and Regulations for Immunization and Testing for Healthcare Workers. This amendment included mandatory influenza vaccinations for all health care workers, students, volunteers, and trainees who have direct patient contact within a health care facility. The purpose of this study was to evaluate the impact of the regulation of mandating influenza vaccination for health care workers in Rhode Island on influenza incidence, hospitalizations, and deaths of residents of long-term care facilities (LTCF). Surveillance data for influenza incidence, hospitalizations, and deaths among residents of LTCF pre and post the policy implementation are analyzed and results presented. Policy and practice implications for public health nursing are discussed.

scholarly journals Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Anne Marie Rosendahl Madsen ◽  
Frederik Schaltz-Buchholzer ◽  
Thomas Benfield ◽  
Morten Bjerregaard-Andersen ◽  
Lars Skov Dalgaard ◽  
...  
Keyword(s):  
Health Care ◽  
Randomised Controlled Trial ◽  
Health Care Workers ◽  
Cumulative Incidence ◽  
Controlled Trial ◽  
Bcg Vaccine ◽  
Care Workers ◽  
Full Protocol ◽  
Randomised Controlled ◽  
Study Participants

Abstract Objectives: The Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID-19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism. The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with SARS-CoV-2, and to reduce the number of hospital admissions among HCW during the COVID-19 pandemic. Hypothesis: BCG vaccination of HCW will reduce absenteeism by 20% over a period of 6 months. Trial design: Placebo-controlled, single-blinded, randomised controlled trial, recruiting study participants at several geographic locations. The BCG vaccine is used in this study on a different indication than the one it has been approved for by the Danish Medicines Agency, therefore this is classified as a phase III study. Participants: The trial will recruit 1,500 HCW at Danish hospitals. To be eligible for participation, a subject must meet the following criteria: Adult (≥18 years); Hospital personnel working at a participating hospital for more than 22 hours per week. A potential subject who meets any of the following criteria will be excluded from participation in this study: Known allergy to components of the BCG vaccine or serious adverse events to prior BCG administration Known prior active or latent infection with Mycobacterium tuberculosis (M. tuberculosis) or other mycobacterial species Previous confirmed COVID-19 Fever (>38 C) within the past 24 hours Suspicion of active viral or bacterial infection Pregnancy Breastfeeding Vaccination with other live attenuated vaccine within the last 4 weeks Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1) b) subjects with solid organ transplantation c) subjects with bone marrow transplantation d) subjects under chemotherapy e) subjects with primary immunodeficiency f) subjects under treatment with any anti-cytokine therapy within the last year g) subjects under treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months h) Active solid or non-solid malignancy or lymphoma within the prior two years Direct involvement in the design or the execution of the BCG-DENMARK-COVID trial Intervention and comparator: Participants will be randomised to BCG vaccine (BCG-Denmark, AJ Vaccines, Copenhagen, Denmark) or placebo (saline). An adult dose of 0.1 ml of resuspended BCG vaccine (intervention) or 0.1 ml of sterile 0.9% NaCl solution (control) is administered intradermally in the upper deltoid area of the right arm. All participants will receive one injection at inclusion, and no further treatment of study participants will take place. Main outcomes: Main study endpoint: Days of unplanned absenteeism due to illness within 180 days of randomisation. Secondary study endpoints: The cumulative incidence of documented COVID-19 and the cumulative incidence of hospital admission for any reason within 180 days of randomisation. Randomisation: Randomisation will be done centrally using the REDCap tool with stratification by hospital, sex and age groups (+/- 45 years of age) in random blocks of 4 and 6. The allocation ratio is 1:1. Blinding (masking): Participants will be blinded to treatment. The participant will be asked to leave the room while the allocated treatment is prepared. Once ready for injection, vaccine and placebo will look similar, and the participant will not be able to tell the difference. The physicians administering the treatment are not blinded. Numbers to be randomised (sample size): Sample size: N=1,500. The 1,500 participants will be randomised 1:1 to BCG or placebo with 750 participants in each group. Trial Status: Current protocol version 5.1, from July 6, 2020. Recruitment of study participants started on May 18, 2020 and we anticipate having finished recruiting by the end of December 2020. Trial registration: The trial was registered with EudraCT on April 16, 2020, EudraCT number: 2020-001888-90, and with ClinicalTrials.gov on May 1, 2020, registration number NCT04373291. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Keywords: COVID-19, Randomised controlled trial, Protocol, BCG vaccine, NSEs/Non-specific effects of vaccines, Heterologous effects of vaccines, Health care workers, Pandemic, Immune training.

scholarly journals COVID-19: first long-term care facility outbreak in the Netherlands following cross-border introduction from Germany, March 2020

2020 ◽  
Author(s):  
Mitch van Hensbergen ◽  
Casper D.J. den Heijer ◽  
Petra Wolffs ◽  
Volker Hackert ◽  
Henriette L.G. ter Waarbeek ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Workers ◽  
Long Term Care ◽  
Care Facility ◽  
Regional Hospital ◽  
Term Care ◽  
Long Term Care Facility ◽  
Cross Border ◽  
Care Workers

Abstract Background: The Dutch province of Limburg borders the German district of Heinsberg, which had a large cluster of COVID-19 cases linked to local carnival activities in February, before any cases were reported in the Netherlands. However, Heinsberg was not included as an area reporting local or community transmission per the national case definition at the time. In early March, two residents from a long-term care facility (LTCF) in Sittard, a Dutch town located in close vicinity to the district of Heinsberg, started experiencing respiratory symptoms and were admitted to the regional hospital at which they were tested for COVID-19. Introduction of the virus could have occurred following the carnival activities in the surrounding area by LTCF visitors or health care workers.Methods: Surveys and semi-structured oral interviews were conducted with all present residents by health care workers during regular points of care for information on new or unusual signs and symptoms of disease. Both throat and nasopharyngeal swabs were taken from residents suspect of COVID-19 for the detection of SARS-CoV-2 by Real-time Polymerase Chain Reaction and whole genome sequencing was performed using a SARS-CoV-2 specific amplicon-based Nanopore sequencing approach. Additionally, twelve random residents were sampled for possible asymptomatic infections.Results: Since the start of the outbreak, nineteen (19%) residents tested positive for COVID-19. Eleven samples were sequenced, along with three random samples from COVID-19 patients hospitalized in the regional hospital at the time of the LTCF outbreak. Conclusions: All samples were linked to COVID-19 cases from the cross-border region of Heinsberg, Germany. Symptoms were reported only in about two third of the cases, and tended to be generally mild. We therefore recommend low-level screening of HCWs and residents following a confirmed COVID-19 case, even in the absence of symptoms. Since the LTCF residents who tested positive did not meet the criteria for suspect cases of COVID-19 at the time, this highlights the importance of cooperation among cross-border partners in order to establish a coordinated implementation of infection control measures in the region on top of national guidelines to limit the spread of infectious diseases such as COVID-19.

Sign in / Sign up

Export Citation Format

Share Document